RT Journal Article
SR Electronic
T1 Rapid surveillance platforms for key SARS-CoV-2 mutations in Denmark
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.25.21265484
DO 10.1101/2021.10.25.21265484
A1 Spiess, Katja
A1 Gunalan, Vithiagaran
A1 Marving, Ellinor
A1 Nielsen, Sofie Holdflod
A1 Jørgensen, Michelle G. P.
A1 Fomsgaard, Anna S.
A1 Nielsen, Line
A1 Alfaro-Núñez, Alonzo
A1 M. Karst, Søren
A1 ,
A1 Mortensen, Shila
A1 Rasmussen, Morten
A1 Lassaunière, Ria
A1 Worsøe Rosenstierne, Maiken
A1 Polacek, Charlotta
A1 Fonager, Jannik
A1 Cohen, Arieh S.
A1 Nielsen, Claus
A1 Fomsgaard, Anders
YR 2021
UL http://medrxiv.org/content/early/2021/10/26/2021.10.25.21265484.abstract
AB Multiple mutations in SARS-CoV-2 variants of concern (VOCs) may increase, transmission, disease severity, immune evasion and facilitate zoonotic or anthoprozoonotic infections. Four such mutations, ΔH69/V70, L452R, E484K and N501Y, occur in the SARS-CoV-2 spike glycoprotein in combinations that allow detection of the most important VOCs. Here we present two flexible RT-qPCR platforms for small-and large-scale screening to detect these mutations, and schemes for adapting the platforms for future mutations. The large-scale RT-qPCR platform, was validated by pair-wise matching of RT-qPCR results with WGS consensus genomes, showing high specificity and sensitivity. Detection of mutations using this platform served as an important interventive measure for the Danish public health system to delay the emergence of VOCs and to gain time for vaccine administration. Both platforms are valuable tools for WGS-lean laboratories, as well for complementing WGS to support rapid control of local transmission chains worldwide.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Exemption for review by the ethical committee system and informed consent was given by the Committee on Biomedical Research Ethics - Capital region in accordance with Danish law on assay development projects.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.